Efficacy of intensive multidisciplinary rehabilitation in Parkinson's disease: a randomised controlled study

Davide Ferrazzoli, Paola Ortelli, Ilaria Zivi, Veronica Cian, Elisa Urso, Maria Felice Ghilardi, Roberto Maestri, Giuseppe Frazzitta, Davide Ferrazzoli, Paola Ortelli, Ilaria Zivi, Veronica Cian, Elisa Urso, Maria Felice Ghilardi, Roberto Maestri, Giuseppe Frazzitta

Abstract

Objective: To evaluate whether a 4-week multidisciplinary, aerobic, motor-cognitive and intensive rehabilitation treatment (MIRT) improves the quality of life (QoL) of patients with Parkinson's disease (PD), in the short-term and long-term period.

Methods: This is a prospective, parallel-group, single-centre, single-blind, randomised clinical trial (ClinicalTrials.gov NCT02756676). 186 patients with PD, assigned to experimental group, underwent MIRT; conversely, 48 patients, assigned to control group, did not receive rehabilitation. Parkinson's Disease Questionnaire-39 was assessed 2 (T0), 10 (T1) and 18 (T2, only experimental group) weeks after the enrolment. We compared T1 versus T0 scores within subjects and delta scores (T1-T0) between subjects. To investigate the long-term effects, we compared T2 and T0 scores in the experimental group.

Results: At T0, no between-group differences in the Global Index Score (GBI) were observed (experimental group: 43.6±21.4, controls: 41.6±22.9, P=0.50). At T1, we did not find significant changes in controls (delta score: 1.2±9.9, P=0.23), and we found an improvement in GBI in the experimental group (delta score: -8.3±18.0, P<0.0001), significant also between subjects (P<0.0001). Comparing T2 versus T0 in the experimental group, the GBI maintained a significant improvement (delta score: -4.8±17.5, P<0.0001).

Conclusions: A rehabilitation treatment such as MIRT could improve QoL in patients with PD in the short-term and long-term period. Even though the single-blind design and the possible role of the placebo effect on the conclusive results must be considered as limitations of this study, the improvement in outcome measure, also maintained after a 3-month follow-up period, suggests the effectiveness of MIRT on the QoL.

Clinical trial registration: NCT02756676: Pre-results.

Conflict of interest statement

Competing interests: None declared.

© Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2018. All rights reserved. No commercial use is permitted unless otherwise expressly granted.

Figures

Figure 1
Figure 1
CONSORT diagram. CONSORT, Consolidated Standards of Reporting Trials; MIRT, Multidisciplinary Intensive Rehabilitation Treatment.
Figure 2
Figure 2
Study design. MIRT, Multidisciplinary Intensive Rehabilitation Treatment; PDQ-39, Parkinson’s Disease Questionnaire-39.

References

    1. Dowding CH, Shenton CL, Salek SS. A review of the health-related quality of life and economic impact of Parkinson’s disease. Drugs Aging 2006;23:693–721. 10.2165/00002512-200623090-00001
    1. Ebrahim S. Clinical and public health perspectives and applications of health-related quality of life measurement. Soc Sci Med 1995;41:1383–94. 10.1016/0277-9536(95)00116-O
    1. Chaudhuri KR, Healy DG, Schapira AH. National Institute for Clinical Excellence. Non-motor symptoms of Parkinson’s disease: diagnosis and management. Lancet Neurol 2006;5:235–45.
    1. Martinez-Martin P, Rodriguez-Blazquez C, Forjaz MJ, et al. . Impact of pharmacotherapy on quality of life in patients with Parkinson’s Disease. CNS Drugs 2015;29:397–413. 10.1007/s40263-015-0247-x
    1. Gallagher DA, Schrag A. Impact of newer pharmacological treatments on quality of life in patients with Parkinson’s disease. CNS Drugs 2008;22:563–86. 10.2165/00023210-200822070-00003
    1. Behari M, Srivastava AK, Pandey RM. Quality of life in patients with Parkinson’s disease. Parkinsonism Relat Disord 2005;11:221–6. 10.1016/j.parkreldis.2004.12.005
    1. Chapuis S, Ouchchane L, Metz O, et al. . Impact of the motor complications of Parkinson’s disease on the quality of life. Mov Disord 2005;20:224–30. 10.1002/mds.20279
    1. Tomlinson CL, Patel S, Meek C, et al. . Physiotherapy versus placebo or no intervention in Parkinson’s disease. Cochrane Database Syst Rev 2012;7:CD002817.
    1. Bloem BR, de Vries NM, Ebersbach G. Nonpharmacological treatments for patients with Parkinson’s disease. Mov Disord 2015;30:1504–20. 10.1002/mds.26363
    1. Goodwin VA, Richards SH, Taylor RS, et al. . The effectiveness of exercise interventions for people with Parkinson’s disease: a systematic review and meta-analysis. Mov Disord 2008;23:631–40. 10.1002/mds.21922
    1. Frazzitta G, Bertotti G, Riboldazzi G, et al. . Effectiveness of intensive inpatient rehabilitation treatment on disease progression in parkinsonian patients: a randomized controlled trial with 1-year follow-up. Neurorehabil Neural Repair 2012;26:144–50. 10.1177/1545968311416990
    1. Frazzitta G, Maestri R, Bertotti G, et al. . Intensive rehabilitation treatment in early Parkinson’s disease: a randomized pilot study with a 2-year follow-up. Neurorehabil Neural Repair 2015;29:123–31. 10.1177/1545968314542981
    1. Ekker MS, Janssen S, Nonnekes J, et al. . Neurorehabilitation for Parkinson’s disease: Future perspectives for behavioural adaptation. Parkinsonism Relat Disord 2016;22:S73–7. 10.1016/j.parkreldis.2015.08.031
    1. Canning CG, Sherrington C, Lord SR, et al. . Exercise for falls prevention in Parkinson disease: a randomized controlled trial. Neurology 2015;84:304–12. 10.1212/WNL.0000000000001155
    1. Smania N, Corato E, Tinazzi M, et al. . Effect of balance training on postural instability in patients with idiopathic Parkinson’s disease. Neurorehabil Neural Repair 2010;24:826–34. 10.1177/1545968310376057
    1. Nieuwboer A, Kwakkel G, Rochester L, et al. . Cueing training in the home improves gait-related mobility in Parkinson’s disease: the RESCUE trial. J Neurol Neurosurg Psychiatry 2007;78:134–40. 10.1136/jnnp.200X.097923
    1. Hirsch MA, Iyer SS, Sanjak M. Exercise-induced neuroplasticity in human Parkinson’s disease: What is the evidence telling us? Parkinsonism Relat Disord 2016;22:S78–81. 10.1016/j.parkreldis.2015.09.030
    1. Petzinger GM, Fisher BE, McEwen S, et al. . Exercise-enhanced neuroplasticity targeting motor and cognitive circuitry in Parkinson’s disease. Lancet Neurol 2013;12:716–26. 10.1016/S1474-4422(13)70123-6
    1. Fontanesi C, Kvint S, Frazzitta G, et al. . Intensive rehabilitation enhances lymphocyte BDNF-TrkB signaling in patients with Parkinson’s Disease. Neurorehabil Neural Repair 2016;30:411–8. 10.1177/1545968315600272
    1. Herman T, Giladi N, Gruendlinger L, et al. . Six weeks of intensive treadmill training improves gait and quality of life in patients with Parkinson’s disease: a pilot study. Arch Phys Med Rehabil 2007;88:1154–8. 10.1016/j.apmr.2007.05.015
    1. Paker N, Bugdayci D, Goksenoglu G, et al. . Effects of robotic treadmill training on functional mobility, walking capacity, motor symptoms and quality of life in ambulatory patients with Parkinson’s disease: a preliminary prospective longitudinal study. NeuroRehabilitation 2013;33:323–8. 10.3233/NRE-130962
    1. Morberg BM, Jensen J, Bode M, et al. . The impact of high intensity physical training on motor and non-motor symptoms in patients with Parkinson’s disease (PIP): a preliminary study. NeuroRehabilitation 2014;35:291–8. 10.3233/NRE-141119
    1. Peto V, Jenkinson C, Fitzpatrick R, et al. . The development and validation of a short measure of functioning and well being for individuals with Parkinson’s disease. Qual Life Res 1995;4:241–8. 10.1007/BF02260863
    1. Giladi N, Manor Y, Hilel A, et al. . Interdisciplinary teamwork for the treatment of people with Parkinson’s disease and their families. Curr Neurol Neurosci Rep 2014;14:493 10.1007/s11910-014-0493-1
    1. Post B, van der Eijk M, Munneke M, et al. . Multidisciplinary care for Parkinson’s disease: not if, but how!. Postgrad Med J 2011;87:575–8. 10.1136/pgmj.2011.241604rep
    1. Rochester L, Espay AJ. Multidisciplinary rehabilitation in Parkinson’s disease: a milestone with future challenges. Mov Disord 2015;30:1011–3. 10.1002/mds.26277
    1. Tan SB, Williams AF, Kelly D. Effectiveness of multidisciplinary interventions to improve the quality of life for people with Parkinson’s disease: a systematic review. Int J Nurs Stud 2014;51:166–74. 10.1016/j.ijnurstu.2013.03.009
    1. van der Marck MA, Munneke M, Mulleners W, et al. . Integrated multidisciplinary care in Parkinson’s disease: a non-randomised, controlled trial (IMPACT). Lancet Neurol 2013;12:947–56. 10.1016/S1474-4422(13)70196-0
    1. van der Marck MA, Bloem BR, Borm GF, et al. . Effectiveness of multidisciplinary care for Parkinson’s disease: a randomized, controlled trial. Mov Disord 2013;28:605–11. 10.1002/mds.25194
    1. Frazzitta G, Bertotti G, Uccellini D, et al. . Parkinson’s disease rehabilitation: a pilot study with 1 year follow up. Mov Disord 2010;25:1762–3. 10.1002/mds.23316
    1. Hughes AJ, Daniel SE, Kilford L, et al. . Accuracy of clinical diagnosis of idiopathic Parkinson’s disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 1992;55:181–4. 10.1136/jnnp.55.3.181
    1. Frazzitta G, Maestri R, Uccellini D, et al. . Rehabilitation treatment of gait in patients with Parkinson’s disease with freezing: a comparison between two physical therapy protocols using visual and auditory cues with or without treadmill training. Mov Disord 2009;24:1139–43. 10.1002/mds.22491
    1. Frazzitta G, Bossio F, Maestri R, et al. . Crossover versus stabilometric platform for the treatment of balance dysfunction in Parkinson’s Disease: a Randomized Study. Biomed Res Int 2015;2015 10.1155/2015/878472
    1. Opara JA, Brola W, Leonardi M, et al. . Quality of life in Parkinson’s disease. J Med Life 2012;5:375–81.
    1. Peto V, Jenkinson C, Fitzpatrick R. Determining minimally important differences for the PDQ-39 Parkinson’s disease questionnaire. Age Ageing 2001;30:299–302. 10.1093/ageing/30.4.299
    1. Ma HI, Saint-Hilaire M, Thomas CA, et al. . Stigma as a key determinant of health-related quality of life in Parkinson’s disease. Qual Life Res 2016;25:3037–45. 10.1007/s11136-016-1329-z
    1. David FJ, Robichaud JA, Leurgans SE, et al. . Exercise improves cognition in Parkinson’s disease: The PRET-PD randomized, clinical trial. Mov Disord 2015;30:1657–63. 10.1002/mds.26291
    1. Duchesne C, Lungu O, Nadeau A, et al. . Enhancing both motor and cognitive functioning in Parkinson’s disease: aerobic exercise as a rehabilitative intervention. Brain Cogn 2015;99:68–77. 10.1016/j.bandc.2015.07.005
    1. Manenti R, Brambilla M, Benussi A, et al. . Mild cognitive impairment in Parkinson’s disease is improved by transcranial direct current stimulation combined with physical therapy. Mov Disord 2016;31:715–24. 10.1002/mds.26561
    1. Uc EY, Doerschug KC, Magnotta V, et al. . Phase I/II randomized trial of aerobic exercise in Parkinson disease in a community setting. Neurology 2014;83:413–25. 10.1212/WNL.0000000000000644
    1. Lawson RA, Yarnall AJ, Duncan GW, et al. . Cognitive decline and quality of life in incident Parkinson’s disease: The role of attention. Parkinsonism Relat Disord 2016;27:47–53. 10.1016/j.parkreldis.2016.04.009
    1. Ferrazzoli D, Ortelli P, Maestri R, et al. . Focused and sustained attention is modified by a goal-based rehabilitation in Parkinsonian Patients. Front Behav Neurosci 2017;11:56 10.3389/fnbeh.2017.00056
    1. Frazzitta G, Bertotti G, Morelli M, et al. . Rehabilitation improves dyskinesias in Parkinsonian patients: a pilot study comparing two different rehabilitative treatments. NeuroRehabilitation 2012;30:295–301. 10.3233/NRE-2012-0758
    1. Picconi B, Centonze D, Håkansson K, et al. . Loss of bidirectional striatal synaptic plasticity in L-DOPA-induced dyskinesia. Nat Neurosci 2003;6:501–6. 10.1038/nn1040
    1. Simola N, Morelli M, Frazzitta G, et al. . Role of movement in long-term basal ganglia changes: implications for abnormal motor responses. Front Comput Neurosci 2013;7:142 10.3389/fncom.2013.00142
    1. Frazzitta G, Morelli M, Bertotti G, et al. . Intensive rehabilitation treatment in parkinsonian patients with dyskinesias: a preliminary study with 6-month followup. Parkinsons Dis 2012;2012:1–4. 10.1155/2012/910454
    1. Ferrazzoli D, Carter A, Ustun FS, et al. . Dopamine replacement therapy, learning and reward prediction in Parkinson’s Disease: implications for rehabilitation. Front Behav Neurosci 2016;10:121 10.3389/fnbeh.2016.00121
    1. Frazzitta G, Maestri R, Bertotti G, et al. . Rehabilitation in Parkinson’s disease: assessing the outcome using objective metabolic measurements. Mov Disord 2010;25:609–14. 10.1002/mds.22871
    1. Frazzitta G, Maestri R, Ghilardi MF, et al. . Intensive rehabilitation increases BDNF serum levels in parkinsonian patients: a randomized study. Neurorehabil Neural Repair 2014;28:163–8. 10.1177/1545968313508474
    1. Ortelli P, Maestri R, Zarucchi M, et al. . Italian validation of the Belastungsfragebogen Parkinson kurzversion (BELA-P-k): a disease-specific questionnaire for evaluation of the subjective perception of quality of life in parkinson’s disease. J Clin Mov Disord 2017;4:12 10.1186/s40734-017-0059-x
    1. Dodel RC, Singer M, Köhne-Volland R, et al. . The economic impact of Parkinson’s disease. An estimation based on a 3-month prospective analysis. Pharmacoeconomics 1998;14:299–312.
    1. Dodel RC, Eggert KM, Singer MS, et al. . Costs of drug treatment in Parkinson’s disease. Mov Disord 1998;13:249–54. 10.1002/mds.870130209
    1. Suh DC, Pahwa R, Mallya U. Treatment patterns and associated costs with Parkinson’s disease levodopa induced dyskinesia. J Neurol Sci 2012;319:24–31. 10.1016/j.jns.2012.05.029
    1. Bloem BR, Munneke M. Revolutionising management of chronic disease: the Parkinson Net approach. BMJ 2014;348:g1838 10.1136/bmj.g1838

Source: PubMed

Szponzorok és közreműködők

Egészségi állapot

Kábítószer-beavatkozások

3
Iratkozz fel